Clareo Health | FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET
FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amsterdam UMC, location VUmc
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Clinically LABC (stage III) or LRR breast cancer (all histological types) with ER+, HER2- and low grade according to Bloom Richardson criteria (grade 1-2)
Females aged 18 years or older at screening
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
Candidates for treatment with curative intent (patients are also allowed for inclusion in the current study if they have undergone recent surgery (\<6 weeks) for current breast cancer and require staging because of unexpected stage III disease)
In case \[18F\]FDG PET/CT has already been performed, patients can be included \<21 days after this scan
History with another cancer within the last 5 years, except non-melanoma skin cancer
Undergoing treatment for current breast cancer such as (neo)adjuvant chemotherapy, hormonal therapy (only in case of Tamoxifen), radiotherapy or investigational drug therapy
Pregnancy or lactating women
Any medical, psychological or social condition that may interfere with the subject's safety and participation in the study, will lead to exclusion from this study
